Organ preservation in rectal cancer: the GRECCAR12 randomized phase 3 trial (NCT02514278)

被引：0
作者：
Vendrely, Veronique [1 ]
Fernandez, Benjamin [2 ]
Giraud, Nicolas [1 ]
Rouanet, Philippe [3 ]
Tuech, Jean-Jacques [4 ]
Cotte, Eddy [5 ]
Lefevre, Jeremie [6 ]
Dubois, Anne [7 ]
Germain, Adeline [8 ]
Camerlo, Antoine [6 ]
Lelong, Bernard [9 ]
Valverde, Alain [10 ]
Lakkis, Zaher [11 ]
Rivoire, Michel [12 ]
Desfourneaux, Veronique [13 ]
Conroy, Thierry [14 ]
Asselineau, Julien [15 ]
Denost, Quentin [16 ]
Frison, Eric [15 ]
Rullier, Eric [2 ]
机构：
[1] CHU Bordeaux, Radiotherapy, Bordeaux, France
[2] CHU Bordeaux, Surg, Bordeaux, France
[3] Inst Canc Montpellier, Surg, Montpellier, France
[4] CHU Rouen, Surg, Rouen, France
[5] CHU Lyon, Surg, Lyon, France
[6] APHP, Surg, Paris, France
[7] CHU Clermont Ferrand, Surg, Lermont Ferrand, France
[8] CHU Nancy, Surg, Nancy, France
[9] IPC, Surg, Marseille, France
[10] La Croix St Simon, Surg, Paris, France
[11] CHU Besancon, Surg, Esancon, France
[12] Ctr Leon Berard, Surg, Lyon, France
[13] CHU Rennes, Surg, Rennes, France
[14] Inst Cancerol Loraine, Oncol, Nancy, France
[15] CHU Bordeaux, USMR, Bordeaux, France
[16] Bordeaux Colorectal Inst, Surg, Bordeaux, France
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
Organ preservation; Rectal cancer; Radiotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1929
引用
收藏
页码：S1533 / S1534
页数：2
相关论文
共 50 条
  • [21] Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy
    Francois, Eric
    Azria, David
    Gourgou-Bourgade, Sophie
    Jarlier, Marta
    Martel-Laffay, Isabelle
    Hennequin, Christophe
    Etienne, Pierre-Luc
    Vendrely, Veronique
    Seitz, Jean-Francois
    Conroy, Thierry
    Juzyna, Beata
    Gerard, Jean-Pierre
    RADIOTHERAPY AND ONCOLOGY, 2014, 110 (01) : 144 - 149
  • [22] Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial
    Fokas, E.
    Fietkau, R.
    Hartmann, A.
    Hohenberger, W.
    Gruetzmann, R.
    Ghadimi, M.
    Liersch, T.
    Stroebel, P.
    Grabenbauer, G. G.
    Graeven, U.
    Hofheinz, R-D
    Koehne, C-H
    Wittekind, C.
    Sauer, R.
    Kaufmann, M.
    Hothorn, T.
    Roedel, C.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1521 - 1527
  • [23] Correlation in Rectal Cancer Between Clinical Tumor Response After Neoadjuvant Radiotherapy and Sphincter or Organ Preservation: 10-Year Results of the Lyon R 96-02 Randomized Trial
    Ortholan, Cecile
    Romestaing, Pascale
    Chapet, Olivier
    Gerard, Jean Pierre
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (02): : E165 - E171
  • [24] Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
    Kiyotaka Okuno
    Toru Aoyama
    Koji Oba
    Noboru Yokoyama
    Nobuhisa Matsuhashi
    Katsuyuki Kunieda
    Yoji Nishimura
    Hiroki Akamatsu
    Takaya Kobatake
    Satoshi Morita
    Takaki Yoshikawa
    Junichi Sakamoto
    Shigetoyo Saji
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 65 - 71
  • [25] Transanal vs laparoscopic total mesorectal excision for rectal cancer: a multicenter randomized phase III clinical trial (TaLaR trial) protocol
    Kang, Liang
    Zeng, Ziwei
    Luo, Shuangling
    Zhang, Hong
    Wang, Quan
    Ren, Mingyang
    Wu, Miao
    Tong, Weidong
    Xu, Qing
    Xiao, Yi
    Wu, Aiwen
    Chen, Yuan-Guang
    Feng, Bo
    Shen, Zhanlong
    Huang, Liang
    Zhang, Xingwei
    Zheng, Minhua
    Wang, Jian-Ping
    GASTROENTEROLOGY REPORT, 2021, 9 (01): : 71 - 76
  • [26] Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial
    Simon S. M. Ng
    Janet F. Y. Lee
    Raymond Y. C. Yiu
    Jimmy C. M. Li
    Sophie S. F. Hon
    Tony W. C. Mak
    Dennis K. Y. Ngo
    Wing Wa Leung
    Ka Lau Leung
    Surgical Endoscopy, 2014, 28 : 297 - 306
  • [27] Randomized phase III trial comparing surgery alone to UFT plus PSK for stage II rectal cancer (JFMC38 trial)
    Okuno, Kiyotaka
    Aoyama, Toru
    Oba, Koji
    Yokoyama, Noboru
    Matsuhashi, Nobuhisa
    Kunieda, Katsuyuki
    Nishimura, Yoji
    Akamatsu, Hiroki
    Kobatake, Takaya
    Morita, Satoshi
    Yoshikawa, Takaki
    Sakamoto, Junichi
    Saji, Shigetoyo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 65 - 71
  • [28] Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial
    Ng, Simon S. M.
    Lee, Janet F. Y.
    Yiu, Raymond Y. C.
    Li, Jimmy C. M.
    Hon, Sophie S. F.
    Mak, Tony W. C.
    Ngo, Dennis K. Y.
    Leung, Wing Wa
    Leung, Ka Lau
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2014, 28 (01): : 297 - 306
  • [29] Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, noninferiority, phase 3 trial
    Sandra-Petrescu, Flavius
    Herrle, Florian
    Burkholder, Iris
    Kienle, Peter
    Hofheinz, Ralf-Dieter
    BMC CANCER, 2018, 18
  • [30] mFOLFOX6 versus mFOLFOX6 D aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)
    Hofheinz, R. -D.
    Herrle, F.
    Dechow, T.
    von Weikersthal, L. F.
    Welslau, M.
    Lettmaier, S.
    Burkart, C.
    Kubicka, S.
    Kochen, L.
    Merx, K.
    Krause, K.
    Ebert, M.
    Roedel, C.
    Fokas, E.
    Ghadimi, M.
    Reissfelder, C.
    Gaiser, T.
    ESMO OPEN, 2024, 9 (09)
12345